Archives

Perfusfind S.L.

Abstract Background Risk-stratifying patients with  (CS) is a major unmet need. The recently proposed Society for Cardiovascular  and Interventions (SCAI) staging system for CS severity lacks uniform criteria defining each stage. Objectives..

Perfusfind S.L.

Abstract Background:    Post-cardiotomy cardiogenic shock (PCCS) remains a life-threatening complication after cardiac surgery. Extracorporeal membrane oxygenation (ECMO) represents the mainstay of mechanical circulatory support for PCCS; however, its availability..

Perfusfind S.L.

Abstract Purpose: The outcomes of immunocompromised patients with cardiogenic shock treated with venoarterial extra‑corporeal membrane oxygenation (VA‑ECMO) are seldom documented, making ECMO candidacy decisions challeng‑ing. This study aims (1) to..

Perfusfind S.L.

Abstract In a recent issue of Intensive Care Medicine, we read with great interest the article by Moyon et al. [1] who retro-spectively studied the outcomes of immunocompromised patients with..

Perfusfind S.L.

Abstract Purpose of review  To examine the evolving landscape of cardiac surgery, focusing on the increasing complexity of patients and the role of mechanical circulatory support (MCS) in managing perioperative..

Perfusfind S.L.

Abstract Predictive survival models have been proposed to esti-mate survival rates in patients with refractory cardio-genic shock considered for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) [1, 2]. Notably, the Survival after..

Perfusfind S.L.

Abstract Over the past decade, extracorporeal life support (ECLS) has gained increasing utilization in the management of refractory cardiogenic shock (CS) with a class IIaC recommendation according to the latest..

Perfusfind S.L.

Abstract Acute myocardial infarction-related cardiogenic shock (AMI-CS) carries a dismal prognosis. Short-term mortality is in the range of 40–50% [1]. Until recently, only treatment of the culprit lesion by percutaneous..

Perfusfind S.L.

Abstract Purpose of review  This article offers an overview of recent randomized controlled trials (RCTs) testing the efficacy of veno-arterial extracorporeal membrane oxygenation (VA ECMO) and microaxial flow pump (mAFP)..

Perfusfind S.L.

Abstract Introduction Mortality rates in cardiogenic shock remain high, especially in patients with SCAI shock stages C to E [1].When hemodynamic status does not improve or worsens despite optimal fluid,..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used to treat refractory cardiogenic shock (CS) or cardiac arrest (CA) over the past decades. Peripheral VA-ECMO increases left ventricular (LV)..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is a cardiac or pulmonary function support system that is used in cases of refractory organ failure in addition to conventional treatment. Currently, Level I..

Perfusfind S.L.

Abstract Background Although cardiogenic shock requiring extracorporeal life support (ECLS) after cardiac surgery is associated with high mortality, the impact of sex on outcomes of post-cardiotomy ECLS remains unclear with..

Perfusfind S.L.

Abstract Aims This study evaluated how well serial pulse pressure (PP) and PP adjusted by the vasoactive inotropic score (VIS) predicted venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning success and clinical..

Perfusfind S.L.

Abstract Aim Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has become a common intervention for patients with cardiogenic shock (CS), often complicated by cardiac arrest (CA). Moderate hypothermia (MH) has shown promise..

Perfusfind S.L.

Abstract Refractory septic shock is associated with a high risk of death. Circulatory support in the form of veno-arterial extracorporeal membrane oxygenation (VA ECMO) may function as a bridge to..

Perfusfind S.L.

Abstract Despite immediate coronary revascularization, mortality of patients experiencing infarct-related cardiogenic shock (AMICS) remains high [1]. Over the past decade, there has been a growing interest in the use of..

Perfusfind S.L.

Abstract Mortality in infarct-related as well as heart failure-associated cardiogenic shock remains high, reaching 40–50% depending on the etiology and severity of cardiogenic shock. Percutaneous active mechanical circulatory support devices..

Perfusfind S.L.

Abstract Background: Cardiogenic shock in children still carries a high mortality risk despite advances in medical therapy. The use of temporary mechanical circulatory supports is an accepted strategy to bridge patients..

Perfusfind S.L.

Abstract Weaning and liberation from VA ECMO in cardiogenic shock patients comprises a complex process requiring a continuous trade off between multiple clinical parameters. In the absence of dedicated international..

Perfusfind S.L.

Abstract Over the past decade, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has expanded rapidly as a salvage strategy to provide temporary circulatory and respiratory support allowing cardiac function recovery or bridging..

Perfusfind S.L.

Abstract The objective was to investigate the outcomes of concomitant venoarterial extracorporeal membrane oxygenation (ECMO) and left ventricular unloading with Impella (ECPELLA) compared with ECMO alone to treat patients affected..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (VA ECMO) has become a standard of care for severe cardiogenic shock, refractory cardiac arrest and related impending multiorgan failure. The widespread clinical use of..

Perfusfind S.L.

Abstract Introduction Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) improves end-organ perfusion in cardiogenic shock but may increase afterload, which can limit cardiac recovery. Left ventricular (LV) unloading strategies may aid..

Perfusfind S.L.

Abstract The utilization of temporary mechanical circulatory support (tMCS) has increased significantly over the last 40 years for stabilization of salvageable patients; however, there has not been much improvement in..

Perfusfind S.L.

Abstract Background: The purpose of this investigation was to evaluate the impact of venoarterial extracorporeal membrane oxygenation (VA–ECMO) integrated hemoadsorption on the reversal of multiorgan and microcirculatory dysfunction, and early..

Perfusfind S.L.

Abstract Objective Although  (ECLS) has increasingly been used for the  of patients with  (CS), the outcomes of those successfully weaned from support remain poorly defined. Methods Of 510 venoarterial ECLS CS patients at..

Perfusfind S.L.

Abstract Background Reliable predictors of outcomes in venoarterial extracorporeal membrane oxygenation (VA-ECMO) therapy are limited. While elevated lactate levels over time have been linked to outcomes in cardiogenic shock (CS),..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (VA-ECMO) shunts venous blood to the systemic arterial circulation to provide end-organ perfusion while increasing afterload that may impede left ventricle (LV) ejection and impair..

Perfusfind S.L.

Abstract BACKGROUND The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock remains unclear...